This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (101)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

A Follow-up Study

MaryEllen Csuka, MD; Guillermo F. Carrera, MD; Daniel J. McCarty, MD

JAMA. 1986;255(17):2315-2319.

Abstract
Cyclophosphamide, azathioprine, and hydroxychloroquine sulfate were prescribed for 31 patients (26 women and five men) with rheumatoid arthritis refractory to conventional therapy. Maintenance drug dosages (mean ±SD) were as follows: cyclophosphamide, 30±24 mg/day; azathioprine, 74±44 mg/day; and hydroxychloroquine sulfate, 210±92 mg/day. Disease suppression began in 30 patients within three to 24 months (mean, nine months). Results after 43 months (range, 12 to 102 months) were as follows: 16, complete remission; seven, near remission; seven, partial disease suppression; one, no response. None remained in prolonged remission without some form of therapy. Treatment was discontinued in three patients because of pulmonary infection (two) or thrombocytopenia (one). Four patients had five malignant neoplasms (surgical cures) before therapy (two breast, one colon, one melanoma, one endometrial); four patients developed a malignant neoplasm during combined drug therapy (one colon, one endometrial, one lung, one erythroleukemia); and three died. The absolute risk of malignancy from combined drug therapy is still unclear. We concluded that (1) combined use of remittive agents may have promise in treatment of severe rheumatoid arthritis; (2) cyclophosphamide should be replaced with a nonalkylating agent; and (3) the place of combined drug therapy remains uncertain in the absence of controlled trials.

(JAMA 1986;255:2315-2319)

Author Affiliations
From the Departments of Medicine (Drs Csuka and McCarty) and Radiology (Dr Carrera), Medical College of Wisconsin, Milwaukee.

Footnotes
Reprint requests to Department of Medicine, Medical College of Wisconsin, 8700 W Wisconsin Ave, Milwaukee, WI 53226 (Dr McCarty).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Rates and predictors of herpes zoster in patients with rheumatoid arthritis and non-inflammatory musculoskeletal disorders
Wolfe et al.
Rheumatology (Oxford) 2006;45:1370-1375.
ABSTRACT | FULL TEXT  

Two is better than one? Combination therapy in rheumatoid arthritis
Choy
Rheumatology (Oxford) 2004;43:1205-1207.
FULL TEXT  

Combination Therapy with Multiple Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis: A Preventive Strategy
Pincus et al.
ANN INTERN MED 1999;131:768-774.
ABSTRACT | FULL TEXT  

The role of anti-malarials in rheumatoid arthritis -- the American experience
Khraishi and Singh
Lupus 1996;5:S41-S44.
ABSTRACT  

The use of antimalarials in combination with other disease modifying agents in rheumatoid arthritis--the French Experience
Kahan and Menkes
Lupus 1996;5:S45-S49.
ABSTRACT  

The use of antimalarials in combination with other disease modifying agents in RA -- the British experience
Duncan and Capell
Lupus 1996;5:S50-S58.
ABSTRACT  

Second-Line Drug Therapy for Rheumatoid Arthritis
Cash and Klippel
NEJM 1994;330:1368-1375.
FULL TEXT  

Relationships Between Knowledge and Experience in the Use of Disease-Modifying Antirheumatic Agents: A Study of Primary Care Practitioners
Stross
JAMA 1989;262:2721-2723.
ABSTRACT  

Cyclosporin A in Severe, Treatment-Refractory Rheumatoid Arthritis: A Randomized Study
Yocum et al.
ANN INTERN MED 1988;109:863-869.
ABSTRACT  

Treatment of the Patient With Rheumatoid Arthritis Refractory to Standard Therapy
Wilder
JAMA 1988;259:2446-2449.
ABSTRACT